A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis | MicrobiomeTrials← Back to trialsNCT05250973
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-03-01Est. Completion: 2026-02-04
Enrollment target: 151 participants Locations- City of Hope, Duarte, California, United States
- Yale, New Haven, Connecticut, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute Emory University, Atlanta, Georgia, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Boston University Medical Center, Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Memorial Sloan Kettering, New York, New York, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- Wake Forest University - Baptist Medical Center, Winston-Salem, North Carolina, United States
- University Hospital of Cleveland, Cleveland, Ohio, United States
- Ohio Health Research Institute, Columbus, Ohio, United States
- West Penn Hospital, Pittsburgh, Pennsylvania, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- VCU Medical Center, Richmond, Virginia, United States
- University of Washington, Seattle, Washington, United States
Other microbiome trials you might be interested in
Alzheimer's Disease
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's D…
Irvine, United StatesEst. completion Sep 3, 2032
PGM3 DeficiencyEosinophilic and/or Atopic DermatitisOSMR DeficiencyPrimary Localized Cutaneous AmyloidosisHereditary Alpha-tryptasemia
Background:
\- Allergic inflammation is central to allergy-related diseases and disorders, such as asthma, food allergi…
Bethesda, United States
Tom Baker Cancer Center, Calgary, Alberta, CanadaCross Cancer Institute, Edmonton, Alberta, CanadaUniversity Health Network UHN Princess Margaret Cancer Centre, Toronto, Ontario, CanadaPeking University First Hospital, Beijing, ChinaPeking University People's Hospital, Beijing, ChinaWest China Hospital Si Chuan University, Chengdu, ChinaFirst affiliated Hospital of Zhejiang University, Hangzhou, ChinaRuijin Hospital Shanghai Jiao Tong University, Shanghai, ChinaCHU de Limoges, Limoges, FranceCentre hospitalier Lyon-Sud, Pierre-Bénite, FranceCHU De Poitiers, Poitiers, FranceCHU Rangueil, Toulouse, FranceCharite Campus Benjamin Franklin, Berlin, GermanyUniversitatsklinikum Essen, Essen, GermanyUniversitaetsklinikum Heidelberg Medizinische Klinik V, Heidelberg, GermanyAlexandra General Hospital of Athens, Athens, GreeceUniversità Degli Studi Di Napoli Federico Ii, Naples, ItalyFondazione IRCCS Policlinico San Matteo, Pavia, ItalyDIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ''LA SAPIENZA'', Roma, ItalyUniversity Medical Center Groningen, Groningen, NetherlandsHospital Maastricht University Medical Center, Maastricht, NetherlandsUMC Utrecht, Utrecht, NetherlandsHosp. Univ. Germans Trias I Pujol, Badalona, SpainHosp Univ Vall D Hebron, Barcelona, SpainHosp Clinic de Barcelona, Barcelona, SpainClinica Univ. de Navarra 1, Madrid, SpainClinica Univ. de Navarra, Pamplona, SpainHosp Clinico Univ de Salamanca, Salamanca, SpainLeicester Royal Infirmary - Haematology, Leicester, United KingdomUniversity College Hospital, London, United KingdomHereditary Corneal DystrophyCorneal AbnormalityCorneal DystrophiesCorneal Dystrophies, Hereditary
The goal of this clinical trial is to evaluate the safety and efficacy of GEB-101 injection in subjects with TGFBI-relat…
Los Angeles, United StatesEst. completion Aug 2027